semaj83/ctmatch_classification huggingface dataset:
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Systemic Lupus Erythematosus (SLE) Male or female subject, major or minor of any age with SLE (defined according to the ACR criteria) Onset pediatric (<18 years) OR Syndromic Lupus (associated with growth retardation, neurological deficit not related to lupus, frostbite, lymphoproliferation, the kidney malformations, heart, lung, brain calcifications) OR Lupus in context with familial consanguinity OR Familial cases (2 cases of SLE related first degree relative) OR related topic of the first degree to a lupus patient participant (if family lupus or related parents) A person or beneficiary entitled to a social security scheme or similar Informed consent signed by the person (or parent / holding parental authority for minors)  none
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 8.0-18.0,  Systemic Lupus Erythematosus (SLE) Subjects who meet the following will be allowed to participate in the study Complete immunization history must be available at time of enrollment Patients will be aged 8-18 years at time of enrollment Patient will have stable disease activity (no changes in >2 points) during the 3 months preceding enrollment Patients can be enrolled as soon as the seasonal IIV is available and prior to the onset of influenza activity in the community. Generally this will be between September 2013-January2014. If feasible, enrollment will end in December 2013, which is usually before influenza circulates widely in the community  Subjects who meet the following will not be allowed to participate in the study Females who are known to be pregnant or breastfeeding Moderate to high SLE disease activity at enrollment (SLEDAI >6) Oral temp ≥100F (≥37.8) within 72 hours prior to vaccination History of allergy to egg or egg products or history of allergic reaction to previous influenza vaccination or vaccine constituent History of Guillain-Barré syndrome after previous immunizations Unstable SLE disease activity during 3 months prior to enrollment (change in score >2) Requirement for high-dose IV Solumedrol and/or Cytoxan pulse therapy during 6 months prior to study Any condition that study site investigator deems would put patient at unacceptable risk of injury or render patient unable to meet requirements of the protocol Received pre-medication with analgesic or antipyretic agents in the 6 hours prior to first vaccination, or planned medication with analgesic or antipyretic in the week following first vaccination. This criterion should not preclude subjects receiving such medication if the need arises. However, pre-medication is to be discouraged
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Lupus Erythematosus, Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus, Discoid Healthy Have Discoid Lupus Erythematosus (DLE) or Subacute Cutaneous Lupus Erythematosus (SCLE) with or without a diagnosis of Systemic Lupus Erythematosus (SLE) Active DLE or active SCLE confirmed by histological analysis (for participants with DLE or SCLE without SLE) Confirmed diagnosis of SLE using American College of Rheumatology and has current or historical positive antinuclear antibodies (ANA) or anti double-stranded deoxyribonucleic acid (anti-dsDNA) (for participants with DLE or SCLE with SLE) An active skin lesion that can be biopsied (for participants with lupus erythematosus)  Known or thought to have a diagnosis of drug-induced lupus An active skin disease that is not a manifestation of lupus erythematosus Has an acute cutaneous lupus erythematosus rash only If taking anti-malarial therapy has not been on a stable dose for at least 8 weeks before Day 1 Participants treated with greater than 10mg/day of prednisone therapy or equivalent in the last 4 weeks prior to Day 1 Positive serology for human immunodeficiency virus antibody, hepatitis B virus, or hepatitis C virus
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Systemic Lupus Erythematosus Fulfill at least 4 diagnostic for SLE defined by American College of Rheumatology Positive antinuclear antibodies (ANA) and/or anti-double stranded DNA (anti-dsDNA) Active SLE disease as defined by score ≥10 despite on-going stable corticosteroid therapy Subjects with stable nephritis may be enrolled years of age or older  Severe active vasculitis, active central nervous system lupus, uncontrolled hypertension or poorly controlled diabetes Malignancy within past 5 years Known to be positive for HIV and/or positive at the screening visit for hepatitis B, or hepatitis C Liver disease Anemia, neutropenia, or thrombocytopenia Active infection requiring hospitalization or treatment with parenteral antibiotics within the past 60 days or history of repeated herpetic viral infections History of active tuberculosis or a history of tuberculosis infection Pregnant or nursing
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Lupus Erythematosus Graft-versus-host Disease Four or more American College of Rheumatology (ACR) for the classification of SLE or 4 or more of the SLICE Involvement of one or more of the following organ systems: renal, neurologic, hematologic, cardiac, pulmonary, gastrointestinal A lack of response to corticosteroids in moderate-to-high doses, and to either an equivalent degree of immunosuppression with azathioprine, methotrexate, cyclosporin, tacrolimus, belimumab, rituximab, mycophenolate mofetil, and/or appropriate other treatment Patients should be eligible for transplantation according to the BMT Policy Manual  Age less than 18 years and over 75 years Any risk of pregnancy Patients who are preterminal or moribund
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Systemic Lupus Erythematosus Received a minimun of 6 months therapy with with belimumab 10 mg/kg in their current SLE belimumab continuation study Be 18 years of age at the Day 0 visit Non-prenant, non-lactating females willing to comply with specific birth control requirements as set forth in the protocol Able to provide written informed consent to participate Subjects who wish to enroll in the control group and the group taking a 6 month belimumab treatment holiday will need a score of 3 or less after the minimum of 6 months belimumab therapy, as well as having C3 and C4 complement levels at or above the lower limit of the central laboratory reference range, and are on a stable SLE treatment regimen during the 30 day screening period prior to Day 0 Subjects who wish to enroll in the long-term discontinuation group have voluntarily withdrawn from their continuation studies  Subjects who have developed clinical evidence of significant, unstable or uncontrolled, acute or chronic diseases not due to SLE, or experienced an adverse event (AE) in their belimumab continuation study that could, in the opinion of the principle investigator, put the subject at undue risk Subjects who have developed any other medical diseases, laboratory abnormalities, or conditions that, in the opinion of the principle investigator, makes the subject unsuitable for the study
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cutaneous Lupus Any male or female 18 years or older of age with a diagnosis of cutaneous lupus by a dermatologist Capable of understanding and willing to provide a signed and dated written voluntary informed consent before any protocol specific procedures are performed Able to complete the study and comply with study instructions, including attending all study visits  Individuals younger than 18 years of age Known allergy or sensitivity to study medication Inability to complete all study-related visits Introduction of any other prescription medication, topical or systemic, for cutaneous lupus while participating in the study
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Rash Due to Epidermal Growth Factor Receptor Inhibitors Age 18 years and older Subjects with any cancer receiving Cetuximab or Panitumumab on a weekly or every 2 weeks basis Scheduled to start Cetuximab or Panitumumab treatment Males or non-pregnant, non-lactating females who are postmenopausal, naturally or surgically sterile, or with a negative subunit hCG pregnancy test immediately prior to study entry Able to understand and provide signed informed consent Ability to reliably apply topical FDX104 and vehicle twice a day to the appropriate part of the face Willingness to minimize sun exposure for 5 weeks from randomization ECOG performance status 0-2  Prior allergic reaction or severe intolerance to Doxcycycline and/or other tetracyclines Prior allergic reaction or severe intolerance to soy or coconut oil Cutaneous metastases on the face or might spread to the face The presence of any active skin disease (e.g., eczema), tattoos or other problems at application site, (i.e., located on the face) that, in the investigator's opinion, could confound the evaluation of the rash or make topical application unacceptable Hair on the face (e.g beard) which would interfere with the application of the study drug or its evaluation ANC <1,500/mm3 (or<1.5x109/L), or Platelet count < 100,000/mm3 (or <100x109/L) Abnormal renal functions: Serum creatinine >1.6 mg/dL or 142umol/L (SI units) or calculated estimated creatinine clearance <40 ml/min1.73 m2 based on Cockcroft and Gault formula Abnormal hepatic functions: Serum Aspartate transaminase (AST) or alanine tansaminase (ALT) >5 institutional upper limit of normal (ULN). Or Total billirubin > 2 x institutional ULN or >5 x institutional ULN if documented liver metastasis Any clinically significant safety laboratory results that, in the opinion of the Investigator, would place the subject at undue risk if the subject were to participate in the study Any clinically significant finding on the physical examination that, in the opinion of the Investigator, would place the subject at undue risk if the subject were to participate in the study
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Lupus Nephritis Diagnosis of Systemic Lupus Erythematosus (SLE) by American College of Rheumatology (ACR) criteria Positive antinuclear antibody (ANA) or positive anti-ds DNA test results at visit -1 or any time within 14 days before visit -1 Active proliferative lupus nephritis, as defined by either of the following Kidney biopsy documentation within the last 3 months of ISN/RPS proliferative nephritis: Class III, Class IV, or Class V in combination with Class III or IV Active urinary sediment and kidney biopsy documentation within the last 12 months of ISN/RPS proliferative nephritis: Class III, Class IV, or Class V in combination with Class III or IV. Active urinary sediment is defined as any one of the following >5 RBC/hpf in the absence of menses and infection >5 WBC/hpf in the absence of infection; or Cellular casts limited to RBC or WBC casts UPCR >1 at study entry based on a 24-hour collection Ability to provide informed consent  New onset lupus nephritis, defined as lupus nephritis for which the participant has not yet been treated with either mycophenolate mofetil or cyclophosphamide Neutropenia (absolute neutrophil count <1500/mm^3) Thrombocytopenia (platelets <50,000/mm^3) Moderately severe anemia (Hgb < mg/dL) Moderately severe hypogammaglobulinemia (IgG <450 mg/dL) or IgA <10mg/dL Positive QuantiFERON TB Gold test results Pulmonary fibrotic changes on chest radiograph consistent with prior healed tuberculosis Active bacterial, viral, fungal, or opportunistic infections Evidence of infection with human immunodeficiency virus (HIV), hepatitis B (as assessed by HBsAg and anti-HBc) or hepatitis C
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-64.0,  Lupus Erythematosus, Systemic age 18 years American College of Rheumatology (ACR) diagnosis of SLE (1997 revised see appendix 1) Severe SLE flare at screening (see also section 5.2.3.2.), defined as a situation in which 1 or more of the following are met Increase in (SLE Disease Activity Index) with 12 or more points New or worse SLE-related activity of major organs, i.e.: central nervous system (CNS-) SLE (includes NPSLE), vasculitis, nephritis, pericarditis and/or myocarditis, myositis, thrombocytopenia < 60, hemolytic anemia < 4.4mmol/L (=7.0g/dL) Refractory disease, defined as persisting or progressive disease activity (SLEDAI > 6 points) despite conventional immunosuppressive treatment and 1 or more of the following failure of the initial induction treatment at six months, for which a switch to another induction therapy regime has already been carried out intolerance or contraindication for cyclophosphamide and mycophenolate mofetil (MMF) exceeding a cumulative dose of 15 gram of cyclophosphamide a second relapse within two years after start of the initial induction therapy  Active pregnancy, as proven by a positive urine beta-HCG (human chorionic gonadotropin) test or a positive serum beta-HCG Significant B-cell depletion (peripheral B-cell counts < 60x10E6) Significant hypogammaglobulinemia (IgG < 8.0 g/L) Immunization with a live vaccine 1 month before screening Active infection at time of screening, as follows Hospitalization for treatment of infection within previous 2 months of day 0 of the study Use of parenteral (intravenous of intramuscular) antibiotics ( including anti-bacterial, anti-viral, anti-fungal or anti-parasitic agents) within previous 2 months of day 0 of the study
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Thrombocytopenia Patients fulfilled the 1997 ACR modified or SLICC classification of SLE； New onset thrombocytopenia: platelet count <30X109/L(by both routine test and citric acid anti-coagulated blood count test) within 3 months  Thrombocytopenia caused by other reasons, including drugs； Positive for active HAV(hepatitis A virus)/HBV(hepatitis B virus) infection Active HIV(human immunodeficiency virus) or HCV(hepatitis C virus) infection Active HP(Helicopter pylori) infection Severe liver and kidney dysfunction； Severe neuropsychiatric lupus； No response to high dose steroid and/or cyclophosphamide 1 month prior to study enrollment； Uncontrolled diabetes or hypertension before entry Active GI bleeding 3 months before entry Intolerant to HCQ in the past treatment history；
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Lupus Erythematosus man and women over 18 YO suffering from SLE (American College of Rheumatology criterias) without SLE flare for 3 months with a signed consent and social security affiliation (required in France)  Viral infection within 15 days Other chronic inflammatory disease People with special protection (defined in articles : L1121 §5-8 et articles L3212-§1-3 of French healt care law)
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-35.0,  Systemic Lupus Erythematosus SLE patients Female patients aged 18-35 years Fulfilling the American College of Rheumatology (ACR) for the classification of SLE Having participated in the investigators' original HPV study in 2010 Able to give written informed consent Controls Women aged 18-35 years, matched those of SLE patients recruited No known chronic medical diseases Having participated in our HPV study in 2010
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 6.0-999.0,  Systemic Lupus Erythematosus diagnosed with lupus by a qualified physician consents to have 23andMe (via a partner) contact the physician to obtain medical record information willing to submit a saliva sample for DNA testing and complete online surveys related to condition at least 6 years old (minors under 18 require parental consent to enroll) access to the internet resides in the United States
Patient description: A 21-year-old female is evaluated for progressive arthralgias and malaise. On examination she is found to have alopecia, a rash mainly distributed on the bridge of her nose and her cheeks, a delicate non-palpable purpura on her calves, and swelling and tenderness of her wrists and ankles. Her lab shows normocytic anemia, thrombocytopenia, a 4/4 positive ANA and anti-dsDNA. Her urine is positive for protein and RBC casts.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Systemic Lupus Erythematosus Eligible male and female subjects, Age ≥ 18 and ≤ 75 years with Body mass index ≥ 18 and ≤ 35 kg/m2 at screening visit Diagnosed SLE (defined by ≥ 4 of the 11 American College of Rheumatology (ACR) classification for SLE) for at least 3 months before screening Moderate to severe SLE disease activity demonstrated by total score ≥ 6, including skin and joint involvement CLASI Activity score ≥ 5 or at least 5 of 66/68 joints with pain and signs of inflammation Positive anti-nuclear antibodies (ANA) test at screening No change in concomitant medication for SLE activity maintenance and symptom control regarding type of medication and dose level for at least 8 weeks prior to baseline (for steroids and NSAIDs/pain medication 2 weeks) Normal electrocardiogram (ECG)  Active, severe neuropsychiatric SLE defined as any neuropsychiatric element scoring BILAG level A disease or lupus nephritis Diagnosed psoriasis Presence or history of malignancy within the previous 5 years Systemic antibiotic treatment within 2 weeks before baseline visit A positive diagnosis for viral hepatitis B or hepatitis C or Human immunodeficiency virus (HIV) or tested positive for tuberculosis as assessed or recent infection with Herpes Zoster or Herpes Simplex (Type 1 and Type 2), Epstein-Barr virus (EBV) or cytomegalovirus (CMV) infection or reactivation at screening Clinically significant hematologic abnormalities attributed to SLE: Haemoglobin < 8 g/dL; Platelets < 50 E9/L; Leucocytes < 2.0 E9/L Active or history of inflammatory bowel disease (including active or history of colitis) Received the following medications Rituximab within the last 48 weeks before screening Belimumab within the last 12 weeks before screening